European Journal of Nuclear Medicine and Molecular Imaging最新文献

筛选
英文 中文
Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617. 骨问题:Ga-68 PSMA PET/CT体积测量可预测骨显性mCRPC患者接受Lu-PSMA-617治疗后的PSA-PFS和OS。
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-09-29 DOI: 10.1007/s00259-025-07556-w
Mehmet Oğuz Kartal,Ayşenur Sinem Kartal,Nazım Coşkun,Mehmet Ali Nahit Şendur,Elif Özdemir
{"title":"Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617.","authors":"Mehmet Oğuz Kartal,Ayşenur Sinem Kartal,Nazım Coşkun,Mehmet Ali Nahit Şendur,Elif Özdemir","doi":"10.1007/s00259-025-07556-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07556-w","url":null,"abstract":"INTRODUCTIONThis study aimed to evaluate the prognostic value of baseline, interim, and change-based (Δ) volumetric parameters derived from PSMA PET/CT imaging in predicting PSA progression-free survival (PSA-PFS) and overall survival (OS) in bone-dominant metastatic castration-resistant prostate cancer (mCRPC) patients treated with [¹⁷⁷Lu]Lu-PSMA-617.METHODSThis retrospective study included 56 bone-dominant mCRPC patients who underwent [⁶⁸Ga]Ga-PSMA PET/CT imaging before and after two cycles of [¹⁷⁷Lu]Lu-PSMA therapy. Quantitative parameters, including SUVmean, PSMA tumor volume (PSMA-TV), and total lesion PSMA activity (TL-PSMA), were extracted using a fixed threshold of SUV ≥ 3. Δ values were calculated as the relative change between baseline and interim scans. Associations with PSA-PFS and OS were analyzed using Cox regression and Kaplan-Meier survival analyses.RESULTSThe presence of new lesions on interim PSMA PET/CT and a reduction of PSMA-TV(Bone) ≤ 10.7% were identified as independent predictors of shorter PSA-PFS (p = 0.022 and p = 0.043, respectively). For OS, an interim PSMA-TV(Bone) > 310.3 mL remained an independent prognostic factor both in the entire cohort (p < 0.001) and in the subgroup without early PSA progression (p = 0.002). While baseline SUVmean values were associated with PSA-PFS, no significant association with OS was observed.CONCLUSIONIn bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA, ΔPSMA-TV(Bone) ≤ 10.7% and the presence of new lesions were independent predictors of PSA-PFS, while interim bone tumor volume was significantly associated with OS. These findings highlight the clinical relevance of bone-specific volumetric parameters, which may serve as a potential alternative to whole-body tumor assessments by providing more practical and targeted prognostic insights in this patient population.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"74 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Superiority of long axial field-of-view 68Ga-PSMA-11 PET over short axial field-of-view PET in prostate cancer: a head-to-head comparison. 长轴位68Ga-PSMA-11 PET比短轴位PET在前列腺癌诊断中的优势:一项头对头的比较
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-09-27 DOI: 10.1007/s00259-025-07546-y
Yining Wang,Lijing Zhu,Lian Xu,Liang Dong,Haitao Zhao,Lianghua Li,Gang Huang,Ruohua Chen,Jianjun Liu
{"title":"Superiority of long axial field-of-view 68Ga-PSMA-11 PET over short axial field-of-view PET in prostate cancer: a head-to-head comparison.","authors":"Yining Wang,Lijing Zhu,Lian Xu,Liang Dong,Haitao Zhao,Lianghua Li,Gang Huang,Ruohua Chen,Jianjun Liu","doi":"10.1007/s00259-025-07546-y","DOIUrl":"https://doi.org/10.1007/s00259-025-07546-y","url":null,"abstract":"BACKGROUND AND PURPOSEPrevious studies have shown that long axial field-of-view (LAFOV) 68Ga-PSMA-11 PET/CT can significantly improve the detection rate compared to short axial field-of-view (SAFOV) 68Ga-PSMA-11 PET/CT in prostate cancer. However, the diagnostic efficiency between the two scans was compared in different cohorts, not directly within the same patients. Whether LAFOV 68Ga-PSMA-11 PET could improve image quality, enhance lesion quantification, and impact patient treatment decisions in the same patients remains unclear. To address this research gap, we performed a direct comparison of LAFOV and SAFOV 68Ga-PSMA-11 PET in the same cohort of prostate cancer patients to evaluate whether LAFOV 68Ga-PSMA-11 PET could enhance lesion identification and modify clinical management compared to SAFOV 68Ga-PSMA-11 PET.METHODSThirty-four patients with prostate cancer undergoing routine 68Ga-PSMA-11 PET/CT were included and underwent a same-day dual-scanning protocol. Half of the patients first underwent a clinically routine SAFOV PET scan using continuous bed motion, followed immediately by LAFOV PET (5-minute acquisition in list mode); the other half underwent scanning in the reverse order. The image quality of LAFOV and SAFOV 68Ga-PSMA-11 PET was compared using subjective scoring and objective parameters. Objective parameters, including maximum and mean standardized uptake values (SUVmax and SUVmean), signal-to-noise ratio (SNR), and tumor-to-background ratio (TBR), were measured and compared.RESULTSLAFOV 68Ga-PSMA-11 PET exhibited superior image quality compared to SAFOV PET based on both subjective and objective parameters. LAFOV 68Ga-PSMA-11 PET had better image quality and higher lesion SUVmax, SNR, and TBR compared to SAFOV PET. In 17.65% of patients, LAFOV 68Ga-PSMA-11 PET detected additional lesions that were unidentified on SAFOV 68Ga-PSMA-11 PET. Compared to SAFOV 68Ga-PSMA-11 PET, LAFOV 68Ga-PSMA-11 PET detected additional lesions in 33.33% of patients with biochemical recurrence and 9.09% of patients with newly diagnosed prostate cancer, leading to significant changes in clinical management.CONCLUSIONSIn this head-to-head comparison, LAFOV 68Ga-PSMA-11 PET demonstrated superior image quality, enhanced lesion detection, and a significant impact on clinical management for both biochemical recurrence and newly diagnosed prostate cancer patients compared to SAFOV 68Ga-PSMA-11 PET. These findings suggest that LAFOV 68Ga-PSMA-11 PET may be the preferred imaging modality for comprehensive prostate cancer evaluation.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"88 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145153530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Head to head comparison of [18F]SiTATE versus [18F]DOPA-PET in patients with neuroendocrine tumors. [18F]SiTATE与[18F]DOPA-PET在神经内分泌肿瘤患者中的头对头比较
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-09-26 DOI: 10.1007/s00259-025-07572-w
Wolfgang Roll,Panayiotis Hadjitheodorou,Emmanouil Alevroudis,Kyriaki Kyrou,Giorgos Adamou,Andreas Fesas,Björn Wängler,Carmen Wängler,Ralf Schirrmacher,Mohammad R Pourkhessalian,Charalambia Kalogirou,Ioannis Tsechelidis,Alexis Vrachimis
{"title":"Head to head comparison of [18F]SiTATE versus [18F]DOPA-PET in patients with neuroendocrine tumors.","authors":"Wolfgang Roll,Panayiotis Hadjitheodorou,Emmanouil Alevroudis,Kyriaki Kyrou,Giorgos Adamou,Andreas Fesas,Björn Wängler,Carmen Wängler,Ralf Schirrmacher,Mohammad R Pourkhessalian,Charalambia Kalogirou,Ioannis Tsechelidis,Alexis Vrachimis","doi":"10.1007/s00259-025-07572-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07572-w","url":null,"abstract":"BACKGROUNDIn neuroendocrine tumors molecular imaging methods play a key role, either targeting the somatostatin receptor or catecholamine pathways. [18F]SiTATE is a somatostatin receptor-targeting peptide that uses silicon fluoride acceptor (SiFA) radiochemistry, overcoming disadvantages of Gallium-68 labelled DOTA compounds. Here we present the first prospective data of [18F]SiTATE compared to [18F]DOPA-PET in NET patients.METHODS38 patients with suspected neuroendocrine tumors were prospectively included. All patients underwent both [18F]DOPA-PET and [18F]SiTATE-PET. The diagnostic performances were compared on a per-patient and per-lesion basis.RESULTS22 of 38 patients did not show [18F]DOPA- or [18F]SiTATE-PET positive disease. [18F]DOPA-PET was rated as the more accurate imaging modality in three cases and [18F]SiTATE-PET in four cases. [18F]SiTATE-PET showed a significantly higher sensitivity on a per lesion basis compared to [18F]DOPA-PET (n = 143; sensitivity [18F]SiTATE: 86.7%; [18F]DOPA: 73.4%; p = 0.016). Relative quantitative uptake values were not significantly different ([18F]SiTATE median Tumor to Background Ratio max (TBRmax): 8.2; [18F]DOPA TBRmax: 6.5; p = 0.247).CONCLUSIONSIn this first prospective study, [18F]SiTATE-PET provided high tumor to background ratios in the majority of NET patients with complementary results to [18F]DOPA-PET.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"3 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145140265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[18F]fluorodeprenyl-D2 PET can detect and monitor astrogliosis in anti-LGI1-IgG autoimmune encephalitis. [18F]氟去戊烯基d2 PET可检测和监测抗lgi1 - igg自身免疫性脑炎的星形胶质细胞形成。
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-09-26 DOI: 10.1007/s00259-025-07531-5
J A Gernert,L Sanzo,H Zimmermann,F S Thaler,L Vogler,J S Gnörich,L Tagnin,S Lindner,B Kugelmann,R Schaefer,G N Bischof,S Katzdobler,R A Werner,G U Höglinger,J Levin,N Franzmeier,B Rauchmann,R Perneczky,M Kerschensteiner,T Kümpfel,M Brendel
{"title":"[18F]fluorodeprenyl-D2 PET can detect and monitor astrogliosis in anti-LGI1-IgG autoimmune encephalitis.","authors":"J A Gernert,L Sanzo,H Zimmermann,F S Thaler,L Vogler,J S Gnörich,L Tagnin,S Lindner,B Kugelmann,R Schaefer,G N Bischof,S Katzdobler,R A Werner,G U Höglinger,J Levin,N Franzmeier,B Rauchmann,R Perneczky,M Kerschensteiner,T Kümpfel,M Brendel","doi":"10.1007/s00259-025-07531-5","DOIUrl":"https://doi.org/10.1007/s00259-025-07531-5","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"23 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145140410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bone marrow scintigraphy as a prognostic marker of overall survival in mCRPC patients treated with Radium-223 dichloride. 骨髓显像作为mCRPC患者接受223二氯化镭治疗后总生存期的预后标志物。
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-09-25 DOI: 10.1007/s00259-025-07589-1
Qaid Ahmed Shagera,Olivier Gheysens,Emilie Jonard,Emmanuel Seront,Renaud Lhommel,Frederic E Lecouvet,Bertrand Tombal,François Jamar
{"title":"Bone marrow scintigraphy as a prognostic marker of overall survival in mCRPC patients treated with Radium-223 dichloride.","authors":"Qaid Ahmed Shagera,Olivier Gheysens,Emilie Jonard,Emmanuel Seront,Renaud Lhommel,Frederic E Lecouvet,Bertrand Tombal,François Jamar","doi":"10.1007/s00259-025-07589-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07589-1","url":null,"abstract":"PURPOSETo evaluate the potential prognostic value of pretherapeutic Bone Marrow Scintigraphy (BMS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with Ra-223 dichloride (Ra-223).METHODSWe analyzed 28 mCRPC patients who performed BMS and treated with Ra-223. Visual image analysis was performed and defined as follows: normal distribution (uptake in the vertebral column and bony pelvis) vs. medullary expansion (uptake at the distal half of femoral and/or humeral diaphysis or more distally). Correlation between medullary expansion status and baseline laboratory factors was performed. Survival analyses for evaluating the association between medullary expansion and other variables with overall survival (OS) were conducted using cox regression hazard model and Kaplan Meier methods.RESULTSA total of 130 doses of Ra-223 were administered, with 17 (60%) patients received 6 cycles. BMS status was significantly correlated with hemoglobin levels (p < 0.001), PSA levels (p = 0.008), the number of prior systemic therapies (p = 0.032) and radiotherapy (p = 0.01). Median OS was 19 months, with 16 patients dead. Among variables tested, BMS status, hemoglobin, number of therapies, and number of Ra-223 cycles were significantly associated with OS (hazard ratios: 3.3, p = 0.02; 0.75, p = 0.042; 1.74, p = 0.019; 4.6, p = 0.006; respectively). Patients with normal BMS had a median OS of 33 months vs. 7.6 months in those with medullary expansion (log-rank 5.5, p = 0.019).CONCLUSIONThis study demonstrated a significant association between medullary expansion status on BMS and OS in mCRPC patients treated with Ra-223. Patients exhibiting medullary expansion have worse outcomes compared to those without expansion. Medullary expansion was correlated with adverse prognostic biomarkers commonly linked to worse outcomes in mCRPC.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"28 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145134138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uridine-Based PET/NIRF Dual-Modality imaging for precision tumor diagnosis and surgery. 基于尿嘧啶的PET/NIRF双模成像用于肿瘤的精确诊断和手术。
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-09-24 DOI: 10.1007/s00259-025-07573-9
Linjie Bian,Panli Li,Yigang Chen,Simin He,Jianping Zhang,Xiaoping Xu,Jindian Li,Shaoli Song
{"title":"Uridine-Based PET/NIRF Dual-Modality imaging for precision tumor diagnosis and surgery.","authors":"Linjie Bian,Panli Li,Yigang Chen,Simin He,Jianping Zhang,Xiaoping Xu,Jindian Li,Shaoli Song","doi":"10.1007/s00259-025-07573-9","DOIUrl":"https://doi.org/10.1007/s00259-025-07573-9","url":null,"abstract":"PURPOSEMetabolic reprogramming allows cancer cells to survive and proliferate under nutrient-deprived conditions. Uridine, a central molecule in pyrimidine metabolism, supports both nucleotide biosynthesis and redox homeostasis. However, high-sensitivity imaging tools for equilibrative nucleoside transporter 1 (ENT1)-mediated uridine transport are lacking, limiting applications in precise diagnosis and intraoperative guidance. This study aimed to develop and validate a novel dual-modality imaging platform targeting ENT1-mediated uridine transport for tumor imaging and surgical navigation.METHODSWe synthesized [68Ga]Ga-DOTA-FZUD and ICG-FZUD probes for PET and NIR-II fluorescence imaging, respectively. Small-animal PET/CT and NIR-II fluorescence imaging were performed, and biodistribution were analyzed. Ex vivo NIR-II fluorescence imaging using ICG-FZUD was performed on surgical specimens from three gastric cancer patients to confirm tumor targeting.RESULTS[68Ga]Ga-DOTA-FZUD exhibited excellent radiochemical purity. In pancreatic cancer models with relatively higher ENT1 expression (AsPC-1, Panc-1) compared with lower ENT1 expression models (MiaPaCa-2, BxPC-3), [68Ga]Ga-DOTA-FZUD demonstrated markedly greater tumor uptake. Similar uptake was also observed in gastric, breast, and glioblastoma models, with tumor-to-muscle ratios consistently exceeding 3.5. ICG-FZUD enabled high-contrast NIR-II imaging and clearly delineated tumor margins. Notably, ICG-FZUD penetrated the blood-brain barrier and visualized orthotopic glioblastoma. Ex vivo imaging of human gastric cancer tissues confirmed selective tumor uptake, consistent with histopathological findings.CONCLUSIONThis ENT1-targeted uridine transport PET/NIRF dual-modality imaging platform complements conventional glucose-based imaging and provides real-time intraoperative navigation. It holds significant promise for early cancer diagnosis and precision surgery with strong translational potential.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"13 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145127316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unexpected radioiodine uptake: when benign tumors mimic thyroid cancer. 意外的放射性碘摄取:当良性肿瘤模拟甲状腺癌。
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-09-23 DOI: 10.1007/s00259-025-07580-w
Andrija Gregov,Roko Granić,Leo Kovač,Tomislav Jukić,Anđela Deak,Lucija Lučev,Gabrijela Buljan,Ana Fröbe,Petra Petranović Ovčariček
{"title":"Unexpected radioiodine uptake: when benign tumors mimic thyroid cancer.","authors":"Andrija Gregov,Roko Granić,Leo Kovač,Tomislav Jukić,Anđela Deak,Lucija Lučev,Gabrijela Buljan,Ana Fröbe,Petra Petranović Ovčariček","doi":"10.1007/s00259-025-07580-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07580-w","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"1 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145116800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival effect of PET/CT-defined occult lymph node metastasis in the newly proposed ninth edition N descriptors: a multicentre study. 新提出的第9版N描述符中PET/ ct定义的隐匿性淋巴结转移的生存影响:一项多中心研究。
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-09-23 DOI: 10.1007/s00259-025-07544-0
Xinchen Shen,Tao Chen,Juemin Yu,Jialiang Wen,Haoran Ji,Zihan Guo,Minglei Yang,Bentong Yu,Yongxiang Song,Yangchun Chen,Long Zhao,Likun Hou,Longbing Ren,Deping Zhao,Yunlang She,Chang Chen,Dong Xie,Jiajun Deng
{"title":"Survival effect of PET/CT-defined occult lymph node metastasis in the newly proposed ninth edition N descriptors: a multicentre study.","authors":"Xinchen Shen,Tao Chen,Juemin Yu,Jialiang Wen,Haoran Ji,Zihan Guo,Minglei Yang,Bentong Yu,Yongxiang Song,Yangchun Chen,Long Zhao,Likun Hou,Longbing Ren,Deping Zhao,Yunlang She,Chang Chen,Dong Xie,Jiajun Deng","doi":"10.1007/s00259-025-07544-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07544-0","url":null,"abstract":"PURPOSETo elucidate the potential reasons for the favourable prognosis of positron emission tomography/computed tomography (PET/CT)-defined occult N2 metastasis and its survival effect in the context of the newly proposed ninth edition N descriptors.METHODSA total of 3565 patients who underwent preoperative PET/CT and surgical resection for non-small cell lung cancer were retrospectively included. Survival analysis was conducted using the Kaplan-Meier method and Cox proportional hazards model.RESULTSThe incidence of single-station involvement was significantly higher (p < .001) in occult N2 metastasis (117/191, 61.3%) compared to evident N2 metastasis (83/198, 41.9%). The survival rates of patients with occult N2a (single-station N2 involvement) and occult N2b (multiple-station N2 involvement) were comparable to those of patients with clinically evident N2a and N2b, respectively (adjusted p >.20 for all). Conversely, single-station involvement was associated with a markedly superior prognosis than multiple-station involvement, whether for patients with occult N2 metastasis (5-year overall survival [OS]: 62.7% vs 50.1%, adjusted p = .04) or patients with clinically evident N2 metastasis (5-year OS: 50.3% vs 36.2%, adjusted p = .03). Cox regression analysis of the pathological N2 population further indicated that multiple-station involvement was a more robust prognostic factor than occult lymph node metastasis.CONCLUSIONSThe favourable prognosis of PET/CT-defined occult N2 metastasis may be attributed to the discrepancy in prognosis and proportion between occult N2a and clinically evident N2b. This external validation provided substantial evidence supporting the reasonableness and robustness of the newly proposed ninth edition N descriptors.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"11 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145116802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preclinical and first-in-human evaluation of novel androgen receptor-targeted PET imaging in prostate cancer. 新型雄激素受体靶向PET成像在前列腺癌中的临床前和首次人体评估。
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-09-23 DOI: 10.1007/s00259-025-07577-5
Shuyi Lin,Xiangwei Wang,Fangning Wan,Jianping Zhang,Xiaoping Xu,Bingxin Gu,Zhongyi Yang,Shaoli Song
{"title":"Preclinical and first-in-human evaluation of novel androgen receptor-targeted PET imaging in prostate cancer.","authors":"Shuyi Lin,Xiangwei Wang,Fangning Wan,Jianping Zhang,Xiaoping Xu,Bingxin Gu,Zhongyi Yang,Shaoli Song","doi":"10.1007/s00259-025-07577-5","DOIUrl":"https://doi.org/10.1007/s00259-025-07577-5","url":null,"abstract":"PURPOSEActivation of androgen receptor (AR) signaling is a hallmark of prostate cancer. Dynamic changes in AR expression exacerbate AR heterogeneity throughout prostate cancer therapy. This study aims to develop a series of 68Ga-labeled Enzalutamide-based positron emission tomography (PET) tracers for AR imaging.METHODS[68Ga]Ga-DOTA-FZAR-1, [68Ga]Ga-DOTA-FZAR-2, and [68Ga]Ga-DOTAGA-FZAR-3 were synthesized and the stability was analyzed in vitro. The AR specificity of the three radiotracers was assessed in vitro using AR-negative and AR-positive prostate cancer cell lines and in vivo using tumor xenograft-bearing mice. Moreover, the first-in-human evaluation of [68Ga]Ga-DOTA-FZAR-2 was conducted in eight patients with prostate cancer.RESULTS[68Ga]Ga-DOTA-FZAR-1, [68Ga]Ga-DOTA-FZAR-2, and [68Ga]Ga-DOTAGA-FZAR-3 were successfully synthesized with a radiochemical purity of more than 99%, and had good stability in vitro. Cellular uptake assays revealed that the radiotracers had the highest, intermediate, and lowest uptake in LNCaP, 22Rv1, and PC-3 cells, respectively, strongly correlating with AR expression levels (P < 0.001). Consistent with cellular uptake, the radiotracers also exhibited a hierarchical uptake pattern (highest to lowest) in tumors of mice bearing LNCaP, 22Rv1 and PC-3 xenografts, respectively. In addition, all three radiotracers were primarily eliminated through the urinary system, as confirmed by ex vivo biodistribution studies. More importantly, first-in-human investigation showed safety and diagnostic value of [68Ga]Ga-DOTA-FZAR-2 in AR-associated prostate cancer patients.CONCLUSIONWe developed and validated a series of 68Ga-labeled Enzalutamide-based PET tracers for AR imaging. Initial preclinical and clinical evidence indicate that [68Ga]Ga-DOTA-FZAR-2 enables noninvasive, whole-body, and dynamic monitoring of AR expression in prostate cancer patients throughout therapy.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"30 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145116803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Jeffrey S. Ross, Kevin R. Moore. Diagnostic imaging: spine 5th edition. Elsevier, 2025 ISBN: 9780443378812. 杰弗里·s·罗斯,凯文·r·摩尔。诊断成像:脊柱第5版。Elsevier, 2025 ISBN: 9780443378812。
IF 9.1 1区 医学
European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-09-23 DOI: 10.1007/s00259-025-07571-x
Luigi Mansi
{"title":"Jeffrey S. Ross, Kevin R. Moore. Diagnostic imaging: spine 5th edition. Elsevier, 2025 ISBN: 9780443378812.","authors":"Luigi Mansi","doi":"10.1007/s00259-025-07571-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07571-x","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"57 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145116799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信